Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 9 studies | 22% ± 4% | |
B cell | 7 studies | 27% ± 8% | |
renal alpha-intercalated cell | 5 studies | 29% ± 9% | |
oligodendrocyte | 5 studies | 23% ± 3% | |
epithelial cell | 4 studies | 41% ± 14% | |
astrocyte | 4 studies | 29% ± 6% | |
glutamatergic neuron | 4 studies | 39% ± 14% | |
macrophage | 3 studies | 29% ± 6% | |
GABAergic neuron | 3 studies | 42% ± 1% | |
oligodendrocyte precursor cell | 3 studies | 27% ± 3% | |
abnormal cell | 3 studies | 19% ± 3% | |
basal cell | 3 studies | 23% ± 5% | |
hepatocyte | 3 studies | 36% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 37% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5010.64 | 1445 / 1445 | 100% | 50.89 | 183 / 183 |
liver | 100% | 5989.29 | 226 / 226 | 100% | 70.40 | 406 / 406 |
prostate | 100% | 4175.61 | 245 / 245 | 100% | 64.89 | 502 / 502 |
uterus | 100% | 5258.00 | 170 / 170 | 100% | 49.99 | 459 / 459 |
brain | 100% | 4991.92 | 2640 / 2642 | 100% | 106.05 | 705 / 705 |
breast | 100% | 5032.56 | 459 / 459 | 100% | 116.39 | 1117 / 1118 |
kidney | 100% | 6646.45 | 89 / 89 | 100% | 73.36 | 899 / 901 |
skin | 100% | 4538.91 | 1808 / 1809 | 100% | 70.83 | 471 / 472 |
ovary | 100% | 5197.49 | 180 / 180 | 100% | 41.52 | 428 / 430 |
lung | 100% | 3734.27 | 577 / 578 | 100% | 56.01 | 1151 / 1155 |
bladder | 100% | 4415.57 | 21 / 21 | 99% | 54.75 | 501 / 504 |
stomach | 100% | 3187.86 | 358 / 359 | 100% | 48.86 | 285 / 286 |
thymus | 100% | 3836.96 | 652 / 653 | 100% | 79.21 | 602 / 605 |
intestine | 100% | 4480.35 | 966 / 966 | 99% | 55.09 | 523 / 527 |
adrenal gland | 100% | 8228.33 | 258 / 258 | 99% | 89.28 | 228 / 230 |
pancreas | 98% | 2484.51 | 323 / 328 | 100% | 62.21 | 178 / 178 |
adipose | 100% | 4519.86 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 5140.32 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 71.37 | 29 / 29 |
muscle | 100% | 15421.39 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3886.09 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 44.41 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 40.37 | 1 / 1 |
eye | 0% | 0 | 0 / 0 | 99% | 54.72 | 79 / 80 |
heart | 96% | 3017.64 | 830 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 93% | 2463.02 | 868 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0007611 | Biological process | learning or memory |
GO_2000638 | Biological process | regulation of SREBP signaling pathway |
GO_0007165 | Biological process | signal transduction |
GO_0051865 | Biological process | protein autoubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0090090 | Biological process | negative regulation of canonical Wnt signaling pathway |
GO_0030968 | Biological process | endoplasmic reticulum unfolded protein response |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0044314 | Biological process | protein K27-linked ubiquitination |
GO_0038061 | Biological process | non-canonical NF-kappaB signal transduction |
GO_0016055 | Biological process | Wnt signaling pathway |
GO_0036503 | Biological process | ERAD pathway |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0043025 | Cellular component | neuronal cell body |
GO_0030425 | Cellular component | dendrite |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0030426 | Cellular component | growth cone |
GO_0036513 | Cellular component | Derlin-1 retrotranslocation complex |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0038023 | Molecular function | signaling receptor activity |
GO_1904288 | Molecular function | BAT3 complex binding |
GO_0034450 | Molecular function | ubiquitin-ubiquitin ligase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0051087 | Molecular function | protein-folding chaperone binding |
GO_0030674 | Molecular function | protein-macromolecule adaptor activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0043130 | Molecular function | ubiquitin binding |
GO_1990381 | Molecular function | ubiquitin-specific protease binding |
Gene name | AMFR |
Protein name | E3 ubiquitin-protein ligase AMFR (EC 2.3.2.36) (Autocrine motility factor receptor) (AMF receptor) (RING finger protein 45) (gp78) Autocrine motility factor receptor AMFR protein |
Synonyms | RNF45 |
Description | FUNCTION: E3 ubiquitin-protein ligase that mediates the polyubiquitination of lysine and cysteine residues on target proteins, such as CD3D, CYP3A4, CFTR, INSIG1, SOAT2/ACAT2 and APOB for proteasomal degradation . Component of a VCP/p97-AMFR/gp78 complex that participates in the final step of endoplasmic reticulum-associated degradation (ERAD) . The VCP/p97-AMFR/gp78 complex is involved in the sterol-accelerated ERAD degradation of HMGCR through binding to the HMGCR-INSIG1 complex at the ER membrane . In addition, interaction of AMFR with AUP1 facilitates interaction of AMFR with ubiquitin-conjugating enzyme UBE2G2 and ubiquitin ligase RNF139, leading to sterol-induced HMGCR ubiquitination . The ubiquitinated HMGCR is then released from the ER into the cytosol for subsequent destruction . In addition to ubiquitination on lysine residues, catalyzes ubiquitination on cysteine residues: together with INSIG1, mediates polyubiquitination of SOAT2/ACAT2 at 'Cys-277', leading to its degradation when the lipid levels are low . Catalyzes ubiquitination and subsequent degradation of INSIG1 when cells are depleted of sterols . Mediates polyubiquitination of INSIG2 at 'Cys-215' in some tissues, leading to its degradation . Also regulates ERAD through the ubiquitination of UBL4A a component of the BAG6/BAT3 complex . Also acts as a scaffold protein to assemble a complex that couples ubiquitination, retranslocation and deglycosylation . Mediates tumor invasion and metastasis as a receptor for the GPI/autocrine motility factor . In association with LMBR1L and UBAC2, negatively regulates the canonical Wnt signaling pathway in the lymphocytes by promoting the ubiquitin-mediated degradation of CTNNB1 and Wnt receptors FZD6 and LRP6 . Regulates NF-kappa-B and MAPK signaling pathways by mediating 'Lys-27'-linked polyubiquitination of TAB3 and promoting subsequent TAK1/MAP3K7 activation . Required for proper lipid homeostasis . . |
Accessions | ENST00000565445.5 ENST00000492830.5 ENST00000567738.1 H3BSK3 ENST00000563664.1 ENST00000290649.10 H3BRK9 Q1RN03 Q9UKV5 R4GNG2 H3BQM3 Q6PGR1 |